Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma

Br J Haematol. 2018 Sep;182(5):739-741. doi: 10.1111/bjh.14871. Epub 2017 Aug 31.

Authors

Adrian Chee¹, Michael S Low^{1

2}, Shahla Vilcassim^{1

3}, Gareth P Gregory^{1

3}, Michael Gilbertson¹, Sumita Ratnasingam¹, George Grigoriadis^{1

3}, Pasquale L Fedele^{1

2}

Affiliations

¹ Monash Haematology, Monash Health, Clayton, Australia.
² Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
³ School of Clinical Sciences at Monash Health, Monash University, Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia.

PMID: 28857117
DOI: 10.1111/bjh.14871

No abstract available

Keywords: bortezomib; multiple myeloma; proteasome inhibitors.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bortezomib / administration & dosage
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Multiple Myeloma / drug therapy*
Multiple Myeloma / pathology
Neoplasm Staging
Prognosis
Retrospective Studies
Time Factors
Treatment Outcome

Substances

Bortezomib